Tables
TABLE 1 REGULATORY FRAMEWORK FOR ORPHAN DRUGS 18
TABLE 2 FUNDED PROJECTS OF 2017 20
TABLE 3 LIST OF ORPHAN DRUGS APPROVED IN THE MARKET 26
TABLE 4 MARKET REVENUE OF TOP 15 DRUGS' 2016 AND 2023 ($BILLION) 44
TABLE 5 MOLECULES IN DEVELOPMENT (2015) 46
TABLE 6 AUTOIMMUNE DISEASES MOLECULES 50
TABLE 7 BLOOD DISORDER MOLECULES 52
TABLE 8 RARE CANCER MOLECULES 52
TABLE 9 BLOOD CANCER MOLECULES 55
TABLE 10 CARDIOVASCULAR DISORDERS MOLECULES 56
TABLE 11 DIGESTIVE DISORDERS MOLECULES 57
TABLE 12 EYE DISORDERS MOLECULES 57
TABLE 13 GENETIC DISORDERS MOLECULES 57
TABLE 14 GROWTH DISORDERS MOLECULES 60
TABLE 15 INFECTIOUS DISORDERS MOLECULES 60
TABLE 16 NEUROLOGIC DISORDERS MOLECULES 61
TABLE 17 RESPIRATORY DISORDERS MOLECULES 62
TABLE 18 TRANSPLANTATION MOLECULES 62
TABLE 19 OTHER DISORDERS MOLECULES IN THE PIPELINE 63
TABLE 20 ORPHAN DRUGS MARKET REVENUE BY REGIONS' 2016-2023 ($BILLION) 65
TABLE 21 TOP 5 ORPHAN DRUGS IN THE US MARKET 66
TABLE 22 REGULATORY AUTHORITIES IN ASIA PACIFIC 69
TABLE 23 NOVARTIS AG: OFFERINGS 76
TABLE 24 NOVARTIS AG: RECENT DEVELOPMENTS 76
TABLE 25 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 82
TABLE 26 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 82
TABLE 27 CELGENE CORPORATION: OFFERINGS 88
TABLE 28 CELGENE CORPORATION: RECENT DEVELOPMENTS 88
TABLE 29 BRISTOL-MYERS SQUIBB: OFFERINGS 92
TABLE 30 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS 92
TABLE 31 SHIRE PLC: OFFERINGS 98
TABLE 32 SHIRE PLC: RECENT DEVELOPMENTS 98
TABLE 33 PFIZER: RECENT DEVELOPMENTS 104
TABLE 34 SANOFI: RECENT DEVELOPMENTS 106
TABLE 35 BAYER AG: RECENT DEVELOPMENTS 107
TABLE 36 ALEXION PHARMACEUTICAL' INC.: RECENT DEVELOPMENTS 108
TABLE 37 BIOGEN PHARMACEUTICALS: RECENT DEVELOPMENTS 109
TABLE 38 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 110
TABLE 39 AMGEN INC.: RECENT DEVELOPMENTS 111

LIST OF FIGURE

Charts
CHART 1 PEST ANALYSIS OF ORPHAN DRUGS MARKET 11
CHART 2 RESEARCH METHODOLOGY OF GLOBAL ORPHAN DRUGS MARKET 13
CHART 3 GLOBAL ORPHAN DRUGS MARKET REVENUE' 2016-2023 ($BILLION) 16
CHART 4 SEGMENTATION OF GLOBAL ORPHAN DRUGS MARKET 21
CHART 5 PORTER 5 FORCES OF ORPHAN DRUGS MARKET 21
CHART 6 MARKET DYNAMICS - DRO ANALYSIS 22
CHART 7 DRO - IMPACT ANALYSIS OF GLOBAL ORPHAN DRUGS MARKET 25
CHART 8 KEY STAKEHOLDERS OF GLOBAL ORPHAN DRUGS MARKET 25
CHART 9 ORPHAN DRUGS MARKET REVENUE BY TYPES SEGMENTATION' 2016 VS. 2023 ($BILLION) 42
CHART 10 BIOLOGICS ORPHAN DRUGS MARKET REVENUE BY TYPES SEGMENTATION' 2016-2023 ($BILLION) 43
CHART 11 NON-BIOLOGICS ORPHAN DRUGS MARKET REVENUE BY TYPES SEGMENTATION' 2016-2023 ($BILLION) 44
CHART 12 ORPHAN DRUGS MARKET SHARE BY APPLICATION SEGMENTATION' 2016 (%) 45
CHART 13 HEMATOLOGY MARKET SHARE' 2016 47
CHART 14 ORPHAN DRUG THERAPEUTIC AREA IN PIPELINE' 2016 49
CHART 15 ORPHAN DRUGS IN PIPELINE' 2016 50
CHART 16 ORPHAN DRUGS MARKET SHARE BY REGIONAL SEGMENTATION' 2016 VS. 2023 (%) 64
CHART 17 ORPHAN DRUGS MARKET REVENUE IN NORTH AMERICA' 2016-2023 ($BILLION) 65
CHART 18 ORPHAN DRUGS MARKET REVENUE IN EUROPE' 2016-2023 ($BILLION) 68
CHART 19 ORPHAN DRUGS MARKET REVENUE IN APAC' 2016-2023 ($BILLION) 70
CHART 20 ORPHAN DRUGS MARKET REVENUE IN REST OF THE WORLD' 2016-2023 ($BILLION) 72
CHART 21 ORPHAN DRUGS MARKET SHARE' 2016 75
CHART 22 NOVARTIS AG: OVERVIEW SNAPSHOT 77
CHART 23 NOVARTIS AG: BUSINESS UNITS 78
CHART 24 NOVARTIS AG: GEOGRAPHIC REVENUE 79
CHART 25 NOVARTIS AG: SWOT ANALYSIS 80
CHART 26 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 84
CHART 27 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 84
CHART 28 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 85
CHART 29 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 86
CHART 30 CELGENE CORPORATION: OVERVIEW SNAPSHOT 88
CHART 31 CELGENE CORPORATION: GEOGRAPHIC REVENUE 89
CHART 32 CELGENE CORPORATION: SWOT ANALYSIS 90
CHART 33 BRISTOL-MYERS SQUIBB: OVERVIEW SNAPSHOT 93
CHART 34 BRISTOL-MYERS SQUIBB: BUSINESS SEGMENTS 94
CHART 35 BRISTOL-MYERS SQUIBB: GEOGRAPHIC REVENUE 96
CHART 36 BRISTOL-MYERS SQUIBB: SWOT ANALYSIS 96
CHART 37 SHIRE PLC: OVERVIEW SNAPSHOT 100
CHART 38 SHIRE PLC: BUSINESS UNITS 101
CHART 39 SHIRE PLC: GEOGRAPHIC REVENUE 102
CHART 40 SHIRE PLC: SWOT ANALYSIS 102